Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study
Brian G. Feagan(Western University), Wulf O. Böcher(Boehringer Ingelheim (Germany)), Olivier Dewit, Mukul Minocha(AbbVie (United States)), Ursula Seidler(Medizinische Hochschule Hannover), Steven J. Padula(Boehringer Ingelheim (Germany)), Denis Franchimont(McGill University Health Centre), Marc Ferrante(Universitair Ziekenhuis Leuven), William J. Sandborn(University of San Diego), Markus F. Neurath(Friedrich-Alexander-Universität Erlangen-Nürnberg), Anne Robinson(AbbVie (United States)), Julián Panés(Hospital Clínic de Barcelona), Kori Wallace(AbbVie (United States)), Ivona Herichova(Boehringer Ingelheim (Austria)), Mohamed I. A. Othman(Zagazig University), Arthur Kaser(University of Cambridge), Jun Zhao(AbbVie (United States)), Geert D’Haens(Amsterdam University Medical Centers), Édouard Louis(Centre Hospitalier Universitaire de Liège), Sudha Visvanathan, Christian P. Selinger(Leeds Teaching Hospitals NHS Trust), David B. Hall(Boehringer Ingelheim (Germany)), Adina Soaita(Boehringer Ingelheim (United States)), Kyung-Jo Kim(Asan Medical Center)
Cited by 157
Related Papers
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
|Nature|2012|4.8k
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k